title: From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.
authors: S
authors: S
authors: Bouchet
authors: S
authors: S
authors: Dulucq
authors: J-M
authors: JM
authors: Pasquet
authors: V
authors: V
authors: Lagarde
authors: M
authors: M
authors: Molimard
authors: F-X
authors: FX
authors: Mahon
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D001549:Benzamides / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D001692:Biological Transport; D006801:Humans; D000068877:Imatinib Mesylate; D042541:Intracellular Space / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D027702:Organic Cation Transporter 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D010879:Piperazines / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001549:Benzamides; D027702:Organic Cation Transporter 1; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib